Four DACH start-ups move to the EIT Health Catapult Finals

The EIT Health Catapult Semi-final was a great success for LenioBio, PhagoMed, Peragraft and CardiLink.

Twenty-one start-ups from across Europe have secured their places at the EIT Health Catapult Final in December. Each team will now pitch their solution to the EIT Health network (one of the largest healthcare communities worldwide including over 150 leading healthcare organisations) at the EIT Health Summit Series.

The seven finalists in each category (Medtech, Biotech and Digital Health) will compete for a podium place and three prizes per category, worth €40,000; €20,000; and €10,000. Additionally, one of the finalists will win the “Alex Casta Audience Award” and get a unique opportunity to have their logo displayed on the Nasdaq Tower in New York’s Times Square, where it will be seen by millions of people worldwide.

The 3-day semi-final event, which has gone virtual for 2020, included 42 start-ups pitching in front of hand-picked jury consisting of healthcare professionals with various fields of expertise, as well as expert-led sessions covering the latest developments from the start-up world – from fundraising and IPOs to Machine learning and AI in healthcare.

Four of our supported start-ups really impressed the judges and will be now going to the next stage of the Catapult journey. LenioBio, PhagoMed, CardiLink and Peragraft will hone their competitive side and get in front of big-name VCs during the finals in December. Additionally, PhagoMed was awarded the Lallianse award and LivingBrain the McDermott Will & Emery, sponsor award consisting of expert advice and coaching.

Meet the DACH finalists:

LenioBio specialises in protein expression solutions. The company’s first product, the cell-free protein expression kit ALiCE®, enables customers, such as producers of medicine or food, to drastically reduce the development costs of protein-based products and to extract difficult-to-produce proteins.

PhagoMed focuses on the development of human therapeutic applications of phages and phage-derived proteins, which show promise in addressing antimicrobial resistance. PhagoMed currently has three active development programmes in the fields of implant-associated infections, urinary tract infections and bacterial vaginosis.

PerAGraft dedicates its efforts to developing patient individualised implants for cardiovascular applications and bringing them into the clinical routine. Their innovation is designed to create a new era in complex aortic aneurysm treatment by providing tailored solutions for each patient.

CardiLink (Germany) makes sure that automated external defibrillators (AEDs) work when needed, via an intelligent connectivity solution. As a next step, CardiLink is creating a vendor-neutral connected ecosystem for health and safety devices.


The full list of finalists is available here.

Tune in on 3 December to see them live –

Congratulations to the start-ups and the best of luck.